Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Cetuximab + Cisplatin + RT in Stage III NSCLC
NCT01102231Phase 2Completed
- Sponsor
- IFCT
- Start
- Mar 2010
- Primary completion
- Jan 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Disease-Control Rate at 16 weeks. Started Mar 2010; status: completed.
02
Drugs
KL-140pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01102231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01102231.